December 10, 2018
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing the risk of hydrocephalus for Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) - a move that is likely to result in label changes - according to the agency’s risk...read more